East Montgomery Times

Fox Chase Cancer Center's Department of Bone Marrow Transplant and Cellular Therapy has been reaccredited by the Foundation for the Accreditation of Cellular Therapy (FACT). The department's Chair expressed satisfaction with the reaccreditation, stating, "We are happy to report that we have been reaccredited for another three years. This reaccreditation serves as an important indication of our qualifications in the competitive field of cellular therapy."

The program at Fox Chase Cancer Center is recognized for meeting and exceeding rigorous criteria established by organizations like FACT. As Fung noted, "Our program consistently meets and exceeds the rigorous criteria established by organizations like FACT based on the high number of transplants we perform, our level of expertise, and the support personnel available for our patients." He added that this distinction assures patients they are receiving care at a facility with high-quality standards.

FACT, a nonprofit corporation founded in 1996 in collaboration with the International Society for Cell and Gene Therapy (ISCT) and the American Society for Transplantation and Cellular Therapy, promotes improvement through establishing standards, education, inspection, and accreditation globally. The accreditation signifies that an institution adheres to stringent standards across all aspects of cellular therapy.

The Bone Marrow Transplant department demonstrated compliance with FACT-JACIE International Standards for various cellular therapy processes. This compliance led to its reaccreditation in several areas including adult allogeneic and autologous hematopoietic progenitor cell transplantation and immune effector cellular therapy.

FACT-JACIE standards are regularly updated by international experts to reflect advancements in cellular therapy. Reaccreditation involves evaluating documentation and conducting onsite inspections to ensure adherence to current FACT standards. FACT remains unique as it addresses all quality aspects related to cellular therapy and cord blood banking.